Radius products include BA058 Injection and BA058 Microneedle Patch.
The BA058 Microneedle Patch uses 3M’s patented Microstructured Transdermal System microneedle technology to administer BA058 through the skin, as an alternative to subcutaneous injection.
The company’s recently concluded Phase 2 human testing of an injectable form of BA058 showed that BA058 increased bone mineral density (BMD) at the lumbar spine and femoral neck (a common osteoporotic fracture site located in the hip joint) after six months of therapy, with greater BMD gains relative to Forteo, the reference drug used in the study.
Radius president and CEO Richard Lyttle said by providing a more convenient treatment alternative to injection can promote improved compliance, the BA058 Microneedle Patch will be well-positioned to drive expansion of the osteoporosis market.